Related Experiment Video
Updated: Jun 10, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Emerging pharmacologic therapies for irritable bowel syndrome
Noriaki Manabe1, Archana S Rao, Banny S Wong
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Charlton 8-110, 200 First Street SW, Rochester, MN 55905, USA.
New therapies for irritable bowel syndrome (IBS) target specific mechanisms. Novel agents like prucalopride and ramosetron show promise for chronic constipation and diarrhea-predominant IBS, respectively.
Area of Science:
- Gastroenterology
- Pharmacology
- Drug Development
Background:
- Irritable bowel syndrome (IBS) treatment is advancing with new therapeutic strategies.
- Understanding IBS pathophysiology drives the development of more selective and effective medications.
Purpose of the Study:
- To review emerging therapies for irritable bowel syndrome (IBS).
- To highlight novel drug classes and their mechanisms of action for IBS management.
Main Methods:
- Review of recent clinical trial data for novel IBS therapies.
- Analysis of drug classes targeting specific receptor pathways and cellular mechanisms.
Main Results:
- Prucalopride (a 5-hydroxytryptamine receptor 4 agonist) is effective for chronic constipation with improved safety.
- Ramosetron (a 5-hydroxytryptamine receptor 3 antagonist) shows efficacy in diarrhea-predominant IBS.
- Secretagogues targeting chloride secretion pathways demonstrate high efficacy and safety for constipation.
Conclusions:
- Emerging therapies, including secretagogues, show significant potential for IBS treatment.
- Future IBS management may incorporate bile acid modulators, anti-inflammatory agents, visceral analgesics, and centrally acting agents.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...